Clinical Trial Update: Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating two doses of Semet (80 mcg and 160 mcg) versus placebo in euthyroid patients with autoimmune thyroiditis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Thyroiditis

Drugs mentioned

• Semet

Snippet

Sponsor: University of Siena | Conditions: Thyroiditis Autoimmune | Phase 2 | Status: UNKNOWN